Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: updated efficacy and safety results from VARGADO Cohort C

被引：0
|
作者：
Grohe, C. [1 ]
Wehler, T. [2 ]
Dechow, T. [3 ]
Henschke, S. [4 ]
Schuette, W. [5 ]
Dittrich, I [6 ]
Hammerschmidt, S. [7 ]
Mueller-Huesmann, H. [8 ]
Schumann, C. [9 ]
Krueger, S. [10 ]
Atz, J. [11 ]
Kaiser, R. [11 ]
机构：
[1] Evangel Lung Clin, Dept Pneumol, Berlin, Germany
[2] Evangel Krankenhaus Hamm GmbH, Hamm, Germany
[3] Oncol Haematol Grp Practice, Ravensburg, Germany
[4] Saarland Univ Hosp, Innere Med 5, Med Klin, Homburg, Germany
[5] Krankenhaus Martha Maria Halle Dolau, Halle An Der Saale, Germany
[6] Lungenklin Lostau, Lostau, Germany
[7] Klinikum Chemnitz gGmbH, Dept Internal Med, Chemnitz, Germany
[8] Bruderkrankenhaus St Josef, Klin Hamatol & Onkol, Paderborn, Germany
[9] Klinikverbund Allgau, Clin Pneumol Thorac Oncol Sleep & Resp Med, Kempten, Germany
[10] Florence Nightingale Hosp, Dept Pulmonol Cardiol & Internal Intens Care, Dusseldorf, Germany
[11] Boehringer Ingelheim Pharma GmbH & Co KG, Med Affairs, Ingelheim, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V238
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [1] Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C
    Grohe, C.
    Wehler, T.
    Dechow, T.
    Henschke, S.
    Schuette, W.
    Dittrich, I.
    Hammerschmidt, S.
    Mueller-Huesmann, H.
    Schumann, C.
    Krueger, S.
    Atz, J.
    Kaiser, R.
    ANNALS OF ONCOLOGY, 2021, 32 : S1018 - S1019
  • [2] Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.
    Grohe, Christian
    Wehler, Thomas
    Dechow, Tobias
    Henschke, Sven
    Schuette, Wolfgang
    Dittrich, Ina
    Hammerschmidt, Stefan
    Mueller-Huesmann, Harald
    Schumann, Christian
    Krueger, Stefan
    Atz, Judith
    Kaiser, Rolf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
    J. Corral
    M. Majem
    D. Rodríguez-Abreu
    E. Carcereny
    Á. A. Cortes
    M. Llorente
    J. M. López Picazo
    Y. García
    M. Domine
    M P. López Criado
    Clinical and Translational Oncology, 2019, 21 : 1270 - 1279
  • [4] Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program
    Corral, J.
    Majem, M.
    Rodriguez-Abreu, D.
    Carcereny, E.
    Cortes, A. A.
    Llorente, M.
    Lopez Picazo, J. M.
    Garcia, Y.
    Domine, M.
    Lopez Criado, M. P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2019, 21 (09): : 1270 - 1279
  • [5] Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO
    Grohe, Christian
    Wehler, Thomas
    Dechow, Tobias
    Henschke, Sven
    Schuette, Wolfgang
    Dittrich, Ina
    Hammerschmidt, Stefan
    Muller-Huesmann, Harald
    Schumann, Christian
    Krueger, Stefan
    Atz, Judith
    Kaiser, Rolf
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (10) : 2010 - +
  • [6] Impact of first-line treatment response on second-line therapy with nintedanib plus docetaxel in advanced lung adenocarcinoma after combined first-line immunochemotherapy
    Grohe, C.
    Wehler, T.
    Henschke, S.
    Dittrich, I
    Hammerschmidt, S.
    Aulmann, C.
    Dechow, T.
    Schiefer, C.
    von der Heyde, E.
    Schuette, W.
    Atz, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 208 - 208
  • [7] Effectiveness of Second-Line Treatment with Nintedanib plus Docetaxel (ND) in Patients with Metastatic Lung Adenocarcinoma
    Cordoba Ortega, J. F.
    Adaniel, C.
    Morales, S.
    Gasol, A.
    Veas, J.
    Rodriguez, A.
    Calles Blanco, A.
    Salud, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S948 - S948
  • [8] Impact of KRAS status on the efficacy of nintedanib plus docetaxel following treatment with first-line immune checkpoint inhibitor plus chemotherapy in patients with adenocarcinoma NSCLC: analysis of cohort C of the non-interventional VARGADO trial
    Grohe, C.
    Wehler, T.
    Henschke, S.
    Hammerschmidt, S.
    Aulmann, C.
    Krueger, S.
    Dittrich, I.
    Schuette, W.
    von der Heyde, E.
    Stammberger, A.
    Bajorat, J.
    Kaiser, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 229 - 229
  • [9] Comprehensive analysis of lung adenocarcinoma patients with gefitinib as first-line, second-line and third-line treatment
    Liu, Daoming
    Wang, Fei
    Chen, Xia
    Shi, Hong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (10): : 20171 - 20178
  • [10] Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer
    Auclin, Edouard
    Benitez-Montanez, Jose
    Tagliamento, Marco
    Parisi, Francesca
    Gorria, Teresa
    Garcia-Campelo, Rosario
    Dempsey, Naomi
    Pinato, David J.
    Reyes, Roxana
    Albarran-Artahona, Victor
    Dall'Olio, Filippo
    Soldato, Davide
    Hendriks, Lizza
    Nana, Frank Aboubakar
    Tonneau, Marion
    Lopez-Castro, Rafael
    Nadal, Ernest
    Kazandjian, Suzanne
    Muanza, Thierry
    Blanc-Durand, Felix
    Fabre, Elizabeth
    Castro, Natalia
    Arasanz, Hugo
    Rochand, Adrien
    Besse, Benjamin
    Routy, Bertrand
    Mezquita, Laura
    LUNG CANCER, 2023, 178 : 116 - 122
12345